Longevity & Mitochondrial

SLU-PP-332

Also known as ERR agonist · exercise mimetic · pan-ERR agonist

PreliminaryInjectable (parenteral, used in animal research)Oral (limited by poor oral bioavailability reported in studies)Not approved by the FDA for any use and not a recognized peptide or dietary-supplement ingredient; it is an unapproved investigational research-tool compound with no IND/NDA on file and no completed registered human trials as of mid-2026. It is not a controlled substance under the DEA, but it is illegal to market, sell, or distribute for human consumption, and products are typically labeled "for research use only." Because it is not an FDA-approved drug, it is not a candidate for legitimate 503A/503B pharmacy compounding. For athletes, the World Anti-Doping Agency (WADA) prohibits it under category S4 (Hormone and Metabolic Modulators), and doping-control assays for its metabolites have been developed.

SLU-PP-332 is a small synthetic molecule (not a peptide) developed at Saint Louis University that acts as a non-selective agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), with the strongest activity at ERRα. By activating these nuclear receptors, it is reported in laboratory and animal studies to switch on gene programs tied to mitochondrial biogenesis, fatty acid oxidation, and oxidative muscle-fiber formation — effects that overlap with the body's natural response to endurance exercise, which is why it is described as an "exercise mimetic." In rodent models it has been studied for effects on energy expenditure, fat mass, insulin sensitivity, and running endurance. As of mid-2026 the evidence base is preclinical: published work is largely in mice and cell-based assays, with no completed registered human clinical trials. It remains a research-tool compound rather than an approved medicine.

Studied / used for

Investigated in animal models for metabolic syndrome and diet-induced obesity
Studied preclinically for effects on energy expenditure and fatty acid oxidation
Investigated for exercise endurance and oxidative skeletal-muscle adaptation
Studied in early models for cardiac/heart-failure metabolism and mitochondrial function
Explored preclinically for kidney aging and age-related mitochondrial decline

Commonly reported side effects

Human safety data are lacking; side effects in people are not established from controlled studies
Theoretical cardiovascular effects (e.g., heart-rate changes) commonly raised given ERR involvement in cardiac metabolism, but not characterized in humans
Possible injection-site reactions commonly reported with parenteral research use
Unknown long-term and off-target effects owing to the compound's broad pan-ERR activity

Preliminary. Mostly early or animal studies. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds